Parkinson's disease: an open label trial of pergolide in patients failing bromocriptine therapy.
نویسندگان
چکیده
Sixty-three patients with Parkinson's disease who failed bromocriptine therapy for various reasons were treated in an open-label trial of pergolide. The data were evaluated in a retrospective manner. Forty-six percent had a good response and tolerated the pergolide. A comparison of the outcomes regarding response and toxicity revealed that bromocriptine and pergolide act differently in individual patients. A trial of pergolide in Parkinsonian patients failing bromocriptine therapy may be therapeutically useful.
منابع مشابه
Effect of bromocriptine and pergolide on pituitary tumor size and serum prolactin.
Forty-two patients with elevated serum prolactin were treated in a randomized, open-label trial with the conventional ergot bromocriptine, or a new ergot pergolide. Before treatment, the patients underwent thorough endocrine evaluation and computed tomographic scan. All patients had prolactin levels greater than 25 ng/ml, and 27 patients had a pituitary mass. Follow-up studies performed after 6...
متن کاملDihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonists.
The present paper reviews clinical studies on the use of dihydroergocriptine (DHEC), an ergot derivative with dopamine agonist activity, for the treatment of Parkinson's disease. This compound is a hydrogenated ergot derivative structurally quite similar to bromocriptine, from which it differs because of the hydrogenation in C9 C10 and the lack of bromine in C2. DHEC has a potent D2-like recept...
متن کاملPergolide Mesilate May Improve Fatigue in Patients with Parkinson’s Disease
OBJECTIVES Fatigue is a complaint frequently encountered among patients with Parkinson's disease (PD). Considering the possible relationship between fatigue and dopaminergic dysfuncion, we investigated the effect of pergolide mesilate (a D2 and D1 dopamine receptor agonist) and bromocriptine (a D2 selective dopamine receptor) in patients with PD. METHODS We evaluated 41 patients with PD and c...
متن کاملNeuroprotection by dopamine agonists.
Research on Parkinson's disease has led to new hypotheses concerning the mechanisms of neurodegeneration and to the development of neuroprotective agents. Recent findings of impaired mitochondrial function, altered iron metabolism and increased lipid peroxidation in the substantia nigra of parkinsonian patients emphasize the significance of oxidative stress and free radical formation in the pat...
متن کاملMedical Malpractice. A Preventive Approach
receptors, the in vivo imaging of dopamine and its receptors, the discovery of new dopamine agonists, the surprise revelation that the relatively simple neurotoxin 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) is an etiologic factor of parkinsonism in humans, and the development of novel approaches to bromocriptine therapy. The volume is divided into six main sections: anatomy, biochemist...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Journal of neurology, neurosurgery, and psychiatry
دوره 51 4 شماره
صفحات -
تاریخ انتشار 1988